Aurinia Pharmaceuticals Inc. (AUPH)
| Market Cap | 1.88B |
| Revenue (ttm) | 283.06M |
| Net Income (ttm) | 287.20M |
| Shares Out | 132.97M |
| EPS (ttm) | 2.07 |
| PE Ratio | 6.85 |
| Forward PE | 16.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,825,506 |
| Open | 13.98 |
| Previous Close | 13.97 |
| Day's Range | 13.52 - 14.23 |
| 52-Week Range | 6.55 - 16.54 |
| Beta | 1.54 |
| Analysts | Buy |
| Price Target | 17.25 (+21.74%) |
| Earnings Date | Feb 26, 2026 |
About AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Can... [Read more]
Financial Performance
In 2025, Aurinia Pharmaceuticals's revenue was $283.06 million, an increase of 20.38% compared to the previous year's $235.13 million. Earnings were $287.20 million, an increase of 4893.08%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AUPH stock is "Buy." The 12-month stock price target is $17.25, which is an increase of 21.74% from the latest price.
News
Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in ...
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided ...
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and twelve months ended December 31...
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. ( AUPH) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Peter Greenleaf - President, CEO & Director Joseph Miller - Chief Financial Officer Greg K...
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided ...
Wall Street Breakfast Podcast: FDA Executive Controversy
Aurinia Pharmaceuticals (AUPH) files a federal lawsuit against FDA's George Tidmarsh for alleged false statements about its lupus nephritis drug. Baidu's (BIDU) Apollo Go robotaxi service matches Waym...
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30,...
Aurinia Pharmaceuticals: Lupkynis Growth And AUR200 Pipeline Justify Buy Rating
Aurinia Pharmaceuticals is rated BUY, driven by strong Lupkynis sales growth and a robust cash position supporting pipeline development. AUPH's Lupkynis leads as the first FDA-approved oral therapy fo...
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at ACR Convergence and ASN Kidney Week 2025.
Aurinia Responds to Now Retracted LinkedIn Post
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Responds to Now Retracted LinkedIn Post.
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)
Aurinia Pharmaceuticals Inc. reported total revenues of $70M in Q2 '25, aided by record Lupkynis net product sales of $66.6M. AUPH management continues to execute well, maintaining positive cash flow,...
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Gregory F. Keenan - Chief Medical Officer Joseph M.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
ROCKVILLE, Md.& EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025.
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025.
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity
I revisit biopharma name Aurinia Pharmaceuticals Inc. for the first time in 2025 after the company reported solid Q1 results in May. The quarter saw Lupkynis net product revenues up 25% year-over-year...
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200).
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025.
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
Aurinia Pharmaceuticals Inc. AUPH reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents.
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - Preside...
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025.
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025.
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Glass Lewis recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--ISS recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.